Can chronic kidney disease really be slowed?

Yes — for many people, meaningfully. Several proven medicines, used together with healthy habits, can slow how fast kidney disease progresses and protect the heart at the same time. In large studies, SGLT2 inhibitors slowed kidney decline substantially. These therapies work best when started early and managed by a kidney specialist.

Can kidney disease be reversed?

Most chronic kidney damage can't be undone, but slowing it down is a very real and worthwhile goal — it can mean more years of healthy kidney function and a better chance of delaying or avoiding dialysis. Some sudden drops in kidney function (acute kidney injury) can partly recover.

What is the best medication to slow kidney disease?

There isn't one single 'best' medicine — the most protection usually comes from combining several. National guidelines describe ACE inhibitors or ARBs, SGLT2 inhibitors, finerenone, and (for some) GLP-1 medicines as complementary 'pillars.' SGLT2 inhibitors are now a foundational therapy for many people with CKD and protein in the urine. Your nephrologist decides which fit you and in what order.

Do I need diabetes to benefit from these treatments?

Not always. Certain SGLT2 inhibitors are approved to protect the kidneys whether or not you have diabetes, when there's chronic kidney disease — often with protein in the urine. Finerenone and GLP-1 medicines are currently used mainly for kidney disease related to type 2 diabetes. Your nephrologist will determine what fits your situation.

What eGFR is too low to start these medicines?

It depends on the medicine, and the thresholds are lower than many people expect. Under current national guidelines, SGLT2 inhibitors are generally started at an eGFR of about 20 or above and often continued even as kidney function falls further. Finerenone is generally started at an eGFR of about 25 or above with normal potassium. Your nephrologist checks your exact numbers.

Are these new medicines safe?

They're FDA-approved, widely used, and backed by large studies. Like all medicines they have possible side effects, and a few require monitoring of labs such as potassium. A small, expected dip in kidney numbers at the start of an SGLT2 inhibitor is normal and not a sign of harm. That's one reason they're best managed by a specialist who watches the right numbers.

Can I take these medicines together?

Often, yes — and that's frequently where the most protection comes from. These therapies work through different mechanisms, so they're designed to be layered. The key is starting and combining them carefully, in the right order, with the right monitoring — exactly what a nephrologist manages.

Why didn't my regular doctor mention these?

Kidney care has changed very quickly, and not every clinician follows it closely. Nephrologists specialize in exactly this. If you have CKD, a kidney specialist can review whether any of these therapies could help protect your kidneys.

Slowing Kidney Disease: Advanced Therapies

The short answer

For most of medical history, chronic kidney disease could only be slowed a little. That has changed. In the last few years, several proven medicines — SGLT2 inhibitors, finerenone, GLP-1 medications, and the long-standing ACE inhibitors and ARBs — have been shown to meaningfully slow kidney disease and protect the heart. At Georgia Nephrology, our physicians layer these therapies to fit each person and monitor them closely.

At a glance

Real reason for hope Several proven medicines can now slow kidney disease and protect the heart.
Four pillars ACE inhibitors/ARBs, SGLT2 inhibitors, finerenone, and GLP-1 medicines.
Not experimental FDA-approved, widely used medicines backed by large studies and national guidelines.
With or without diabetes Certain SGLT2 inhibitors protect kidneys either way; others target diabetes-related CKD.
Monitored closely Some require lab checks (like potassium) — a reason to be managed by a specialist.
Personalized Your nephrologist matches and layers therapies to you, then adjusts over time.

There is real reason for hope

If you’ve been told your kidney function is declining, here is something important to know: kidney care has changed dramatically in just the last few years.

Not long ago, doctors had only a couple of ways to slow kidney disease. Today there are several proven medicines that can slow it down — and protect your heart at the same time. For many people, that means more years of healthy kidney function and a real chance to stay off dialysis longer, or avoid it altogether.

These aren’t experimental treatments. They are FDA-approved, widely used medicines backed by large studies and recommended in current national kidney guidelines. The challenge nationally is that many people who could benefit aren’t offered them — often simply because their care isn’t being managed by a kidney specialist who follows this fast-moving field closely.

That’s exactly what we do. Caring for metro Atlanta’s kidneys since 1976, Georgia Nephrology stays current with the newest proven therapies, and we tailor them to each person we see.

4 pillars

make up modern kidney protection — and used together, their benefits add up to more than any one medicine alone.

Kidney disease can now be slowed. The medicines exist. The studies are strong. What matters is making sure the right people are actually offered them.

This page is the deeper dive on the medicines themselves. For the full picture of how we put a plan around them — labs, blood pressure, diet, and follow-up — see our CKD management page. To understand the disease itself, see our in-depth chronic kidney disease guide.

What changed: the “pillars” of modern kidney protection

Kidney specialists now talk about several pillars of treatment that work together to protect your kidneys. Each does something a little different, so they’re often layered — building a stronger wall around your kidney function than any one medicine could alone. Your nephrologist decides which ones are right for you, based on your kidneys, your other health conditions, and how you respond.

Here’s what those pillars are, in plain language.

1. ACE inhibitors and ARBs

Blood-pressure medicines that have been the foundation of kidney protection for decades. Beyond lowering blood pressure, they lower the pressure inside the kidney’s tiny filters and reduce protein leaking into the urine — which is why they’re first-line when there’s albuminuria. If you take a medicine ending in “-pril” (like lisinopril) or “-sartan” (like losartan), this is likely why.

2. SGLT2 inhibitors

One of the biggest changes in kidney care. First developed for diabetes (such as dapagliflozin and empagliflozin), large studies found they also slow kidney disease and protect the heart — whether or not you have diabetes. National guidelines now treat them as a foundational therapy for many people with CKD and protein in the urine. They’re a once-a-day pill, and one of the most effective tools we have.

3. Finerenone

A nonsteroidal medicine (an “MRA”) that calms a specific kind of harmful activity in the kidney linked to scarring and inflammation. In large studies of people with chronic kidney disease related to type 2 diabetes, it slowed kidney decline and lowered heart risks. It’s often added on top of the medicines above for extra protection — and it needs potassium monitoring.

4. GLP-1 medicines

You may know medicines like semaglutide as diabetes or weight treatments. A major kidney study showed semaglutide also slows kidney disease progression and lowers the risk of death from heart and kidney causes in people with type 2 diabetes and CKD. It’s the newest pillar for the right patients.

A note on finerenone: researchers are also studying it in kidney disease without diabetes, with encouraging early results — an area we follow closely.

And the basics still matter. Alongside these medicines, the fundamentals do real work: controlling blood pressure and blood sugar, managing diet and weight, staying active, not smoking, and being careful with medicines that can stress the kidneys (like regular use of certain pain relievers). The newest therapies work best on top of a solid foundation — not instead of it. (If diabetes is driving your kidney disease, see our diabetic kidney disease guide; if you have protein in your urine, see proteinuria.)

Who is a candidate for these therapies?

There’s no single answer that fits everyone — that’s the whole point of seeing a specialist. But broadly, current national guidelines point to who tends to benefit from each pillar:

ACE inhibitors or ARBs — generally recommended when there’s protein in the urine (albuminuria), with or without diabetes, and to help control blood pressure.
SGLT2 inhibitors — generally for people with CKD whose kidney filtering (eGFR) is roughly 20 or above, often with protein in the urine, with or without diabetes. Once started, they’re frequently continued even as kidney function declines further.
Finerenone — generally for people with CKD related to type 2 diabetes whose eGFR is roughly 25 or above, who have protein in the urine, and whose potassium is in the normal range.
GLP-1 medicines — increasingly used for people with type 2 diabetes and CKD, where studies show kidney and heart benefits (and they can help with weight and blood sugar too).

These are general guideposts, not rules — eGFR thresholds, urine-protein levels, your other conditions, and your current medicines all factor in. Your nephrologist checks your exact numbers and history before recommending anything.

How we decide what’s right for you

There’s no single “kidney pill” that’s right for everyone. Part of the value of seeing a nephrologist is having someone who can:

Match the therapy to you — your kidney numbers (eGFR and urine protein), your diabetes status, your heart health, your other medicines, and your preferences all matter.
Layer treatments safely — these medicines are often most powerful in combination, because they work through different mechanisms — but they have to be started and combined carefully, in the right order.
Watch the right labs — some of these therapies can affect potassium levels or cause a small, expected dip in kidney numbers at the start. We monitor for this so we can keep you on protective treatment safely.
Adjust over time — kidney disease changes, and your treatment should keep pace.

This is ongoing, personalized care — not a one-time prescription. It works hand in hand with our overall CKD management plan.

Wondering whether one of these therapies could help you?

Request an Appointment

Monitoring and safety: why a specialist matters

The fact that these medicines need a little watching isn’t a drawback — it’s precisely why managing them is a specialist’s job, and why the people who do best are usually those under a nephrologist’s care.

A small, early dip in kidney numbers is normal. When you start an SGLT2 inhibitor, your eGFR may tick down slightly at first and then stabilize. This is expected and not a sign the medicine is harming your kidneys — but knowing the difference takes experience.
Potassium is watched with finerenone. Because finerenone can raise potassium, we start it only when potassium is in the normal range and recheck it after starting and over time, adjusting if needed.
Combinations are sequenced carefully. Layering pillars is powerful, but the timing and order matter. We add and adjust one step at a time so we can see how you respond.
Your other medicines are reviewed. Some drugs interact, and a few common over-the-counter products can stress the kidneys. We factor your whole medication list into the plan.

The monitoring these therapies need isn’t a reason to avoid them — it’s the reason to have a kidney specialist managing them.

Access to research and newer treatments

Through the Georgia Nephrology Research Institute, some of our patients can take part in clinical studies — which can mean access to promising treatments before they’re widely available. It’s part of how we stay at the leading edge of kidney care.

What this means for you

If you have chronic kidney disease, the most important step you can take is to be cared for by a kidney specialist who knows these therapies and keeps up with the evidence. The medicines exist. The studies are strong. What matters now is making sure the right people are actually offered them — and that’s the standard of care we hold ourselves to.

A few things you can do:

Don’t stop any prescribed medicine on your own — talk with us first.
Keep your lab appointments — they tell us how your kidneys are responding and keep your treatment safe.
Ask questions. If you’re wondering whether one of these therapies could help you, bring it up. That’s exactly the conversation we want to have.

To learn more about the disease itself, see our in-depth chronic kidney disease guide, or our overall CKD management approach.

Related conditions & services